In Webinar, Expert Discusses Strategies to Improve Quality of Life

The key topics of discussion during a new webinar for people with pulmonary fibrosis (PF) focused on strategies — ranging from getting appropriate vaccines and managing individual symptoms to taking advantage of palliative and support care — for improving patient quality of life. The talk was given by Marlies…

Next month is the five-year anniversary of when I first heard the words “idiopathic pulmonary fibrosis.” I was diagnosed by a pulmonologist at a local respiratory care center, where I’d finally been referred after 13 months of dealing with persistent shortness of breath, dry cough, and fatigue. I try…

CohBar has chosen CB5138-3 as its lead treatment candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, based on its promising safety, efficacy, and drug-like properties in preclinical studies. The company is planning to further test this peptide — a small protein fragment — in early studies…

Galecto was advised to stop enrolling and treating patients at high dose and certain ones at low dose in its Phase 2b GALACTIC-1 trial of GB0139, an investigational inhaled therapy for idiopathic pulmonary fibrosis (IPF). The recommendation — made by an independent data safety and monitoring board (DSMB) that…

Suppressing MDM4, a mechanosensitive protein produced by myofibroblasts — the main drivers of pulmonary fibrosis (PF) — promoted the death and clearance of myofibroblasts and reversed persistent lung scarring in a mouse model, a study shows. Notably, these benefits were associated with a reduced stiffness of the extracellular matrix (ECM),…

I have mixed feelings about getting the COVID-19 vaccine. It’s not what you might expect, though. I am not conflicted about whether I should get it. I am not afraid or suspicious of it. I don’t think the vaccine’s fast creation makes it unreliable or unpredictable — merely unprecedented.

Tiny particles, or nanoparticles, coated with a peptide called GSE4 prevented some features of idiopathic pulmonary fibrosis (IPF) and eased others in a rat model of this disease, scientists report. No harmful effects were associated with the use of these GSE4-loaded nanoparticles in the animals, the team added, suggesting they should…

Exposure to certain work- and environment-related elements may be the cause of some idiopathic pulmonary fibrosis (IPF) cases, a recent meta-analysis shows. In particular, exposure to pesticides and agricultural work seem to be factors associated with an increased risk of a person developing IPF. Additionally, exposure to metal dust…